



Novogen in 2016

Presentation to Extraordinary General Meeting of Shareholders

Dr James Garner
Chief Executive Officer

Sydney, NSW
18th March 2016

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of, customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

It takes hundreds or thousands of experimental compounds to deliver one new medicine




The process of drug development is costly, time-consuming, and high-risk

Cost of Developing One New Medicine	Time to Develop One New Medicine	Probability of Success for a Phase I Compound
US\$ 2.6 billion	12½ years	9%

Source: DiMasi JA, Grabowski, HG. *Manage Decis Econ.* 2007;28:469-479; Paul S et al. *Nat Rev Drug Disc.* 2010; 9; DiMasi et al., *Clin Pharmacol Ther.* 2013;94(3):329-35

Competition is fierce

Number of Active Clinical Trials (March 2016)



Source: ClinicalTrials.gov

Despite the challenges of the work, our task is vital

Patient Video

Novogen is well-equipped to contribute to the fight against cancer

Well-Funded

~\$ 38 million cash at bank
~2+ years of funding

Strong Science


2 independent technology platforms
3 drug candidates

Capable Team

>50% of staff are PhD graduates
Inventors of all IP are with company

Novogen has maintained its share price since Jan '15, despite rights issue and adverse sector sentiment


Share Price (AU\$)



Source: Bloomberg

Our priority for 2016 is to transform from a discovery company to a development company

Exploratory
Scientific
Discovery



Focused
Clinical
Development



